Overview
The Top Runner of New Anti-Virus Drugs' R&D In China

Ginkgo Pharma Co., Ltd is a clinical-stage pharmaceutical company focused on the research and development of a cure to address a spectrum of large, unmet medical needs. Our mission is to advance clinical drug candidates discovered with our innovative technology into safe and effective medicines.

We have a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a wide range of human diseases including chronic hepatitis C, influenza, and chronic hepatitis B.

Our management team, scientists and advisors have extensive experience of successfully researching and developing innovative drugs with meaningful clinical and commercial impact, which positions us well to maximize the potential of our drug discovery approach.

Chen Li M.D. & Ph.D. CEO & Chairman of Board

Dr. Chen Li is the founder of Ginkgo and now serves as the CEO and chairman of Ginkgo’s board. He has rich experience in enterprise operation and acquired the EMBA of CEIBS in 2009. By far Dr. Chen has presided over a number of projects concerning the R&D of innovative drugs and obtained more than 10 patents.

Management Team
  • Emily LeeVP & Member of Board

    Emily became the vice president and member of Ginkgo’s board since 2017. She has rich experience in medical BD, registration of new drugs and clinical research.

  • Zhai PeibinMedical Director

    Dr. Zhai peibin serves as the medical director in Ginkgo with more than 10 years of experience in R&D of technology and project management.

  • Shao QingMedicinal Chemistry Manager

    Dr. Shao Qing serves as the medicinal chemistry manager in Ginkgo and has spent 8 years of his career at researching and developing innovative drugs.

Scientific Advisory Board
  • Zhang Fujie, Ph.D.

    Dr. Zhang Fujie has rich experience in the field of viral disease prevention and now serves as the director of the Infection Center of Beijing Ditan Hospital Capital Medical University and the member of the review committee of CDE.

  • Chen Gang, Ph.D.

    Dr. Chen Gang used to be the chairman of the Department of Biostatistics of Anti-tumor Drug Review Center in FDA for almost 8 years. Previously he was the head of Anti-tumor Drug Development Statistics in Johnson & Johnson from 2003 to 2013, and served as the head of Johnson & Johnson’s Quantitative Science Department in China Area from 2013 to 2016.

  • 网站流量监控代码